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ABSTRACT
Background: Defects in the small intestinal epithelial
barrier have been associated with inflammatory bowel
disease but their role in the causation of disease is still a
matter of debate. In some models of disease increased
permeability appears to be a very early event. The
interleukin 10 (IL10) gene-deficient mouse spontaneously
develops colitis after 12 weeks of age. These mice have
been shown to have increased small intestinal perme-
ability that appears early in life. Furthermore, the
development of colitis is dependent upon luminal agents,
as animals do not develop disease if raised under germ-
free conditions.
Aims: To determine if the elevated small bowel
permeability can be prevented, and if by doing so colonic
disease is prevented or attenuated.
Methods: IL10 gene-deficient (IL10
2/
2) mice) were
treated with AT-1001 (a zonulin peptide inhibitor), a small
peptide previously demonstrated to reduce small intest-
inal permeability. Small intestinal permeability was
measured, in vivo, weekly from 4 to 17 weeks of age.
Colonic disease was assessed at 8 weeks in Ussing
chambers, and at 17 weeks of age inflammatory
cytokines and myeloperoxidase were measured in the
colon. Colonic permeability and histology were also
endpoints.
Results: Treated animals showed a marked reduction in
small intestinal permeability. Average area under the
lactulose/mannitol time curve: 5.36 (SE 0.08) in controls
vs 3.97 (SE 0.07) in the high-dose AT-1001 group,
p,0.05. At 8 weeks of age there was a significant
reduction of colonic mucosal permeability and increased
electrical resistance. By 17 weeks of age, secretion of
tumour necrosis factor a (TNFa) from a colonic explant
was significantly lower in the treated group (25.33 (SE
4.30) pg/mg vs 106.93 (SE 17.51) pg/ml in controls,
p,0.01). All other markers also demonstrated a clear
reduction of colitis in the treated animals. Additional
experiments were performed which demonstrated that
AT-1001 was functionally active only in the small
intestine.
Conclusions: This work suggests that increased
intestinal permeability may be an important aetiological
event in the development of colitis in IL10
2/
2 mice.
Increased intestinal permeability has been pro-
posed as a cause of systemic disease for decades. In
several autoimmune diseases such as diabetes,
Crohn’s disease and coeliac disease, increased
intestinal permeability has been recognised as an
early feature of the disease. In Crohn’s disease,
increased intestinal permeability has been
described in non-inflamed portions of the gut, as
well as in healthy first-degree relatives of patients,
suggesting that this defect can occur independently
of inflammation.
1–5 However, whether this is an
epiphenomenon, an early manifestation of disease
or a critical step in disease pathogenesis is
unknown and has been the subject of much
debate.
Intestinal barrier function involves dynamic and
complex structures located at the junctions
between intestinal epithelial cells. These junctions
open and close continually in response to physio-
logical
6–8 and pathogen-induced stimuli.
9–10 One of
several physiological pathways implicated in
increased intestinal permeability is the zonulin
pathway. This pathway was postulated following
the observation of the interaction between the
bacterial pathogen Vibrio cholerae and the intestinal
epithelial barrier. One of the several toxins
produced by this bacterium, the zonula occludens
toxin (ZOT), increases intestinal permeability.
This toxin and its mammalian homologue zonulin
is thought to bind to an apical membrane receptor
on the enterocyte.
11 Activation of this pathway
initiates a cascade of intracellular events that
involve phosphorylation of tight junction proteins
and opening of the paracellular space.
12 Zonulin
secretion has been reported to be upregulated in
coeliac disease,
13 type 1 diabetes
14 and in dermatitis
herpetiformis.
15 It has been suggested that the
resultant increase in small intestinal permeability
observed in these conditions is secondary to
zonulin secretion and may be important in the
pathogenesis of these diseases.
A synthetic octapeptide corresponding to amino
acids in the receptor-binding motif of zonulin has
been synthesised as a zonulin inhibitor. This
zonulin peptide inhibitor (AT-1001) competitively
blocks the apical zonulin receptor and prevents the
opening of tight junctions secondary to zonulin.
11
This inhibition is believed to only occur in the
small intestine as the ZOT/zonulin receptor has
been found in the jejunum and distal ileum, but
not in the colon.
16 We elected to use this
compound, given chronically in the water supply,
to determine whether increased small intestinal
permeability could be prevented in the interleukin
10 gene deficient (IL10
2/
2) mouse.
This mouse develops a patchy, chronic colitis
similar to human Crohn’s disease.
17 From the point
of view of this study, the IL10
2/
2 mouse model of
disease has two important features. First, these
animals have been described as having increased
small intestinal permeability from very early in life
and well before the onset of disease.
18 Second,
disease development is dependent upon luminal
factors; it does not occur in animals raised under
germ-free conditions. These observations suggested
that the colitis observed in these animals might
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ability with increased presentation of a luminal agent to the
mucosal immune system. This is a hypothesis that we have
previously proposed for several other autoimmune diseases.
19
Perhaps the best evidence suggesting that increased intestinal
permeability has an aetiological role in autoimmune disease
comes from the BB rat model of diabetes. In these animals
autoimmune type 1 diabetes develops spontaneously in animals
fed a normal diet, but can be prevented with a hydrolysed diet.
We have previously demonstrated that these animals have
increased gastric and small intestinal permeability even when
receiving a hydrolysed diet.
20 Furthermore, the expression of
diabetes in animals consuming a normal diet can also be
prevented by abolishing the increase in intestinal permeability
with the zonulin receptor antagonist AT-1001.
21 These data
strongly suggest that, at least in this animal model of
autoimmune disease, dietary antigens can initiate disease
through a mechanism that involves increased gastrointestinal
permeability. It also provides support for the concept that there
may be novel means of preventing some autoimmune diseases
by targeting increases in gastrointestinal permeability.
Therefore the goals of this study were 2-fold. First, we wished
to determine whether the previously reported leakiness of the
small intestine could be prevented by treating IL10
2/
2 animals
with a zonulin receptor inhibitor. Second, if we could prevent
the increase in small intestinal permeability observed in these
animals would this prevent or ameliorate the subsequent
colitis?
MATERIALS AND METHODS
Animals
Homozygous IL10
2/2 mice generated on a 129 Sv/Ev genetic
background, and 129 Sv/Ev controls were housed under
specific pathogen-free conditions until weaning (3 weeks),
when they were moved to conventional animal housing. The
mice were housed in high-efficiency particulate air (HEPA)
filter cages and fed a standard mouse chow diet. These mice
were bred and raised in the animal facility at the University of
Alberta.
Pharmacological therapy
IL10
2/
2 mice aged 3.5 weeks and 129 Sv/Ev controls were
randomised into four groups (n=10–13 for each group).
Starting at 4 weeks of age, two groups of IL10
2/
2 mice were
treated with AT-1001 in their drinking water, whereas one
group of IL10
2/
2 mice and one group of 129 Sv/Ev mice did not
receive the treatment. The drinking water of the two treatment
groups was prepared daily by dissolving either 0.1 mg/ml (low
dose) or 1.0 mg/ml (high dose) of AT-1001 in filtered distilled
water. Placebo groups drank filtered distilled water prepared
daily as well. Mice were treated until 17 weeks of age, when
they were killed by cervical dislocation.
In separate experiments, 10–12-week-old IL10
2/
2 mice and
129 Sv/Ev mice were given the zonulin receptor agonist AT-
1002 (1 mg/ml) or AT-1002 mixed with AT-1001 (1 mg/ml
each) in the drinking water for 24 h. A control group was given
bovine serum albumin (1 mg/ml). Mice were placed in meta-
bolic cages during these 24 h for urine collection.
AT-1001 and AT-1002 were graciously provided by Alba
Therapeutics (Baltimore, Maryland, USA) as a neat, powdered
chemical.
Ussing chamber assay
Mice were killed at 8 weeks of age by cervical dislocation and a
segment of colon removed. The mucosa was mounted in Lucite
chambers exposing mucosal and serosal surfaces to 10 ml of
oxygenated Krebs buffer (in mmol/l: 115 NaCl, 8 KCl, 1.25
CaCl2, 1.2 MgCl2,2K H 2PO4, 225 NaHCO3; pH 7.35). The
buffers were maintained at 37uC by a heated water jacket and
circulated by CO2/O2. Fructose (10 mmol/l) was added to the
serosal and mucosa sides. For measurement of basal mannitol
fluxes, 1 mmol/l of mannitol with 370 KBOr of
3H was added to
the mucosal side. The spontaneous transepithelial potential
difference (PD) was determined, and the tissue was clamped at
zero voltage by continuously introducing an appropriate short-
circuit current with an automatic voltage clamp (DVC 1000
World Precision Instruments, Sarasota, Florida, USA). Tissue
ion resistance (1/G), where G is conductance, was calculated
from the potential difference and short-circuit current according
to Ohm’s law.
22
Figure 1 Increased small intestinal permeability precedes colonic disease. (A) small intestinal permeability measurements from 4 to 17 weeks in
interleukin 10 gene-deficient (IL10
2/
2) mice (closed circles) and Sv/Ev 129 wild-type mice (open circles) show a marked difference between these
animal models very early in age. (n=10–13 at each time point). (B) Concentration of interferon c (IFNc) in the small intestine of IL10
2/
2 (closed
circles) and wild-type mice (open circles) at 4, 8 and 17 weeks of age. (C) Concentration of tumour necrosis factor a (TNFa) in the small intestine of
IL10
2/
2 (closed circles) and wild-type mice (open circles) at 4, 8 and 17 weeks of age. For both cytokines, a significant difference was observed
between the IL10
2/
2 and wild-type mice only at 17 weeks. (p,0.001; n=4–7).
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Once every week, all mice were housed in metabolic cages after
a 4 h fast of food and water and immediately after a gavage of
0.2 ml of a sugar probe containing 100 mg of sucrose, 12 mg of
lactulose, 8 mg of mannitol and 6 mg of sucralose. To
compensate for the 4 h without zonulin inhibitor treatment,
experimental mice were fed 30 ml, by pipette, of a solution
containing either 0.083 mg (low dose) or 0.83 mg (high dose) of
AT-1001, 45 min before placing them in metabolic cages.
Placebo groups received 30 ml of filtered distilled water. After
the collection of urine the animals were placed in their
respective cages, and provided with food and water.
Urine from each animal was collected for 22 h in
collection tubes, treated with 100 ml of a 10% thymol
solution (1.0 g/10 ml isopropanol) and paraffin oil (100 mlt o
prevent urine evaporation). Samples were frozen at 270uC
until analysis. All sugars were quantified by ion exchange
high-performance liquid chromatography (HPLC) as pre-
viously described.
23 Briefly, cellobiose was added as an
internal standard, and the urine was filtered through a
0.4 mm filter and diluted as necessary. Samples were
deionised and then injected on a Dionex MA-1 ion exchange
column (Dionex, Sunnyvale, California, USA). Sugars were
eluted with NaOH at a flow rate of 0.4 ml/min. Peaks were
detected using pulsed amperometric detection on a Dionex
HPLC and quantified as peak areas. Final data were reported
as either fractional excretions (sucrose and sucralose) or as a
ratio of fractional excretions (lactulose/mannitol). Fractional
excretion is defined as the fraction of the gavaged dose
recovered in the urine sample.
Sucralose was also assayed by HPLC. Separation was achieved
using a Dionex Ionpac NS1 column and acetonitrile–water as
Figure 2 Small intestinal permeability is reduced with a zonulin
antagonist AT-1001. (A) Small intestinal permeability was measured in
IL10
2/
2 mice treated with high dose AT-1001 (open squares), low dose
(open circles) or placebo (closed circles) from 4 to 17 weeks of age. The
shaded area represents the mean (3 SD) of the lactulose/mannitol ratios
observed in wild-type mice. Mice treated with the high dose of AT-1001
eventually reached the wild-type range. (B) Statistical analysis of the
areas under the curve of small intestinal permeabilities for each group.
The permeabilities of the groups treated with AT-1001 differed
significantly from the placebo group; p,0.05 (low dose), p,0.01 (high
dose), n=10–13.
Figure 3 The zonulin peptide inhibitor AT-1001 reduced small intestinal
permeability by 8 weeks. (A) Mannitol flux was measured in Ussing
chambers at 8 weeks of age and was increased in the interleukin 10
gene-deficient (IL10
2/
2) mice (p,0.05). This increase was not observed
in animals treated with AT-1001 (n=4–8). (B) The electrical resistance
was reduced in the IL10
2/2 mice only (p,0.01). AT-1001 treatment
prevented this reduction (n=5–8). WT, wild-type mice.
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with an electrochemical detector in a fashion identical to the
other sugars. For these assays, the internal standard used was
phenyl-b-D-thiogalactoside (Sigma Chemical, Oakville, Ontario,
Canada) added to the initial urine sample at a concentration of
0.1 mg/ml.
Mucosal cytokine secretion
At 4, 8 and 17 weeks of age, colonic organ cultures were
prepared from control mice, IL10
2/
2 mice, and IL10
2/
2 mice
treated with AT-1001. Because of the patchy nature of colitis in
IL10
2/
2 mice whole colons were removed, flushed with PBS,
and a quarter of the tissue was cut longitudinally and
resuspended in tissue culture plates (Falcon 3046; Becton
Dickinson Labware, Lincoln Park, New Jersey, USA) in RPMI
1640 supplemented with 10% fetal calf serum, penicillin
(100 U/ml), streptomycin (100 U/ml). Cultures were incubated
at 37uCi n5 %C O 2. After 24 h, supernatants were harvested and
stored at 270uC for analysis of cytokine levels. Pellets were left
to dry for 4 days and weighed. TNFa and IFNc levels in cell
supernatants were measured using enzyme-linked immunosor-
bent assay (ELISA) kits (Medicorp, Montreal, Quebec, Canada).
Myeloperoxidase assay
At 17 weeks of age, a section of the colon of all animals was
removed upon dissection, weighed and immediately flash-
frozen. Samples were kept at 270uC until determination of
myeloperoxidase (MPO) concentrations. Levels of MPO in
colonic tissue were measured using an ELISA kit (Cell
Sciences, Canton, Massachusetts, USA).
Histological injury grading
Upon sacrifice, proximal, mid, distal ileum and whole colon
were harvested and fixed in 10% phosphate-buffered formalin.
These samples were embedded in paraffin in toto, sectioned at
4 mm, and stained with haematoxylin & eosin for light
microscopy examination. The slides were reviewed in a blinded
fashion by a pathologist (JSD) and were assigned a histological
score for intestinal inflammation using a scheme modified from
Saverymuttu et al.
24
Statistical analysis
Data are expressed as means (SEM). Comparisons between
groups were made using ANOVA with a Tukey test for post hoc
comparisons. All calculations were performed using Graphpad
Prism 3.0, and significance was assumed at p,0.05.
RESULTS
Permeability
To determine whether there was a primary permeability defect
in IL10
2/
2 mice, we examined small intestinal permeability
from 4 to 17 weeks of age and compared it to wild-type mice.
The IL10
2/
2 mice showed an increased small intestinal
permeability from 4 weeks onwards compared to the Sv/Ev
129 wild-type mice (fig 1A). The proinflammatory cytokines
IFNc and TNFa have been shown to be elevated in the colon of
this animal in the presence of colitis.
18 In order to establish
whether the small intestinal permeability defect preceded
colitis, we measured the secretion of these cytokines in the
colon at 4, 8 and 17 weeks of age. As shown in fig 1B,C the
IL10
2/
2 and wild-type mice produced similar levels of IFNc and
TNFa at 4 and 8 weeks but their cytokine secretion levels were
significantly greater at 17 weeks of age, when the animals
exhibited colitis. Clearly, abnormal small intestinal permeability
preceded the development of colitis by this criterion.
To determine whether the increased small intestinal perme-
ability was zonulin dependent the animals were treated with
AT-1001. When given daily in the drinking water the zonulin
antagonist AT-1001 was effective in decreasing small intestinal
permeability in the IL10
2/
2 mice (fig 2). After 4 weeks of
treatment, high-dose AT-1001 reduced small intestinal perme-
ability to levels observed in control animals. This was evident
from 8 weeks of age (fig 2A). The animals treated with low dose
AT-1001 showed a significant reduction in overall permeability
(as expressed as the area under the permeability curve) as
compared to the placebo group (fig 2B), but this dose did not
quite return small intestinal permeability to normal levels
(fig 2A).
A similar attenuation effect was observed histologically.
These results are illustrated in fig 7. Significant inflammation
was observed in the IL10
2/
2 mice which was similar to that
observed in those treated with the low dose of AT-1001.
However, those animals treated with the high dose of the
compound had a significant reduction in this histological score,
although it was still significantly greater than the scores
observed in the control animals.
The effect of AT-1001 in reducing small intestinal perme-
ability was also evident in vitro at 8 weeks of age. As
demonstrated in fig 3, small intestinal permeability to mannitol
and electrical resistance were determined in Ussing chambers.
Both doses of AT-1001 effectively reduced permeability to
mannitol in the small intestine (fig 3A). Furthermore, the loss of
electrical resistance, observed in the IL10
2/
2 animals, was
prevented in the high dose treated group, but not in the low
dose treated group (fig 3B).
Inflammation
To test whether or not decreasing small intestinal permeability
would affect the development of colonic disease, we evaluated
several parameters of colonic disease. Over the entire course of
the experiment we non-invasively determined epithelial colonic
damage using the clearance of orally administered sucralose.
Additional markers of colitis included in vitro colonic perme-
ability at 8 weeks of age, and at 17 weeks of age, colonic
cytokine secretion, MPO content and histology.
At 8 weeks of age colonic permeability to mannitol was
increased in the IL10
2/
2 animals with a corresponding decrease
in electrical resistance. In the treated animals these changes
were largely prevented and both treated groups showed similar
results to wild-type mice (fig 4A,B). This suggests that the early
evidence of colonic disease, observed in IL10
2/
2 mice, is
prevented or delayed by treatment with AT-1001.
Colonic damage was measured weekly using sucralose
excretion (fig 5). IL10
2/
2 mice and controls excreted similar
amounts of sucralose in their urine until week 10, following
which they started showing elevated amounts of sucralose
(fig 5A). IL10
2/
2 animals had a significantly increased cumula-
tive amount of damage as compared to the wild-type animals
(fig 5B). Both treated groups had significantly less damage than
the IL10
2/
2 animals but still significantly more than the wild-
type group. Treatment with AT-1001 appears to have been
significantly ameliorated, but not completely prevented colonic
disease as determined by this parameter.
At 17 weeks of age, IFNc and TNFa secretion in the colon
was clearly reduced in the groups treated with AT-1001. Only
the IL10
2/
2 group showed significantly increased rates of
cytokine secretion compared to the wild-type animals
Inflammatory bowel disease
44 Gut 2009;58:41–48. doi:10.1136/gut.2008.150888(fig 6A,B). Neutrophil infiltration in the colon, as measured by
tissue MPO content (fig 6C), was increased in the IL10
2/
2 and
low dose AT-1001 mice as compared to controls but was not
significantly increased in the high dose treated group. Taken
together, these data suggest that treatment with AT-1001,
active in the small intestine was effective at reducing the colonic
inflammation observed in these animals.
Representative examples of the colonic histology are pre-
sented in fig 7. The upper panels are taken at620 magnification
whilst the lower are at 640. In fig 7B, panels a/b illustrate the
histological features observed in the background strain of
animals with only a sprinkling of inflammatory cells in the
lamina propria. This is in contrast to the IL10
2/
2 mice shown in
panels c/d where there is a marked increase in the inflammatory
cell compartment. Panels e/f and g/h are representative sections
taken from animals treated with the low and high doses of AT-
1001, respectively. It can be appreciated that the inflammatory
changes observed in these animals are less than those seen in the
IL10
2/
2 mice.
It has been suggested that the zonulin receptor is absent in
the colon; however, that work was done in rabbits, not mice.
16
Therefore, to rule out the possibility that this pathway is
present in the colon and that the effects observed throughout
our experiments were a consequence of the drug in the colon,
we performed a functional assay to test for the presence of a
zonulin effect in the colon using a zonulin peptide agonist (AT-
1002). As observed in fig 8, after challenge with this agent, only
small intestinal permeability was increased, while sucralose
excretion stayed the same. This was true for both the IL10
2/2
and wild-type mice. Using increasing concentrations of AT-1002
Figure 4 Attenuation of colonic permeability at 8 weeks. (A) Colonic
mannitol flux was increased in the interleukin 10 gene-deficient (IL10
2/2)
mice (p,0.05). This increase was prevented by the zonulin peptide
inhibitor AT-1001 (n=5–8). (B) Electrical resistance was reduced in the
IL10
2/2 mice and again prevented by AT-1001 (p,0.05, n=5–8). WT,
wild-type mice.
Figure 5 The zonulin peptide inhibitor AT-1001 attenuates colonic
damage. (A) Sucralose excretion was measured weekly in interleukin 10
gene-deficient (IL10
2/
2) mice treated with a high dose of AT-1001 (open
squares), low dose (open circles) or placebo (closed circles) from 4 to
17 weeks of age. The data are shown relative to that from wild-type
(WT) animals, which is represented in the shaded area. As noted in the
text colonic damage becomes evident at 10 weeks of age but is reduced
in AT-1001 animals. (B) Statistical analysis of the areas under the curve
of sucralose excretion for each group. The sucralose excretion of IL10
2/2
mice was significantly higher than that from wild-type animals
(*p,0.01). Sucralose excretion of the animals treated with AT-1001
differed significantly from that of the IL10
2/2 mice (**p,0.05,
n=10–13), suggesting that AT-1001 reduces but does not prevent
colonic damage.
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mannitol ratio was dose dependent and at no dose, up to the
solubility limit of AT-1002, did we observe any effect in the
colon (data not shown). When both wild-type and IL10
2/2
animals were treated with a combination of AT-1001 and AT-
1002, the increase in small intestinal permeability was
abolished, demonstrating that the effect of AT-1002 to increase
small intestinal permeability could be prevented or blocked by
the same agent we used in the previous experiments.
DISCUSSION
The aetiology of Crohn’s disease is poorly understood.
However, it has been proposed that three main features must
be present for disease to occur: (1) a genetically susceptible
mucosal immune system; (2) an antigen, or pro-inflammatory
compound, which reaches the gut and can trigger the
susceptible immune system; and (3) an alteration in gut barrier
function which allows this antigen to have contact with the
mucosal immune system.
19 In this regard the IL10 deficient
mouse is an interesting model of human Crohn’s colitis. It does
not develop colitis in the absence of intestinal bacterial flora,
suggesting that one or more components within the enor-
mously complex flora trigger the susceptible mucosal immune
system to develop inflammation.
The experiments presented here provide evidence that a break
in small intestinal barrier function is necessary for colitis to occur
in the IL10
2/
2 mouse. This and other animal models of Crohn’s
disease,includingthesenescenceacceleratedpronemouse(SAMP)
and the mouse downregulated in adenoma (mdra) deficient
mouse have shown increased small intestinal permeability well
before disease expression.
25–27 This study extends these observa-
tions in an important manner by demonstrating that reversal of
this barrier defect can attenuate the disease, implying that the
increased permeability is not simply an epiphenomenon but
rather is an important aetiological event.
Our in vivo measurements of small intestinal permeability
indicated that these mice demonstrate abnormal small intestinal
permeability at 4 weeks of age, which is as early a time point as
we can measure. In fact it has been previously demonstrated that
this defect can be detected using ex vivo techniques at 2 weeks of
age, in the absence of histological injury.
25 In this study we
measured the secretion of proinflammatory cytokines as a marker
of disease,
25 28 and by this criteria demonstrated that increased
small intestinal permeability preceded disease.
Normal gastrointestinal permeability is tightly regulated and
the mechanisms involved are, for the most part, unknown.
However, recent work suggests that one biological pathway that
regulates permeability involves zonulin. This hormone appears to
be secreted into the lumen and activates an apical receptor which
initiates a cascade of events culminating in the opening of the
tight junction. The identification of this pathway has also
provided an opportunity for pharmacological manipulation of
increased permeability associated with over-activity of this
pathway. Because zonulin receptors are not present in colonic
epithelium,
16 drugs thatworkvia this mechanism should not have
effects in the colon. To confirm that this was true in our mice, we
tested whether a zonulin-mediated event could be elicited in the
colon under conditions identical tothose used in our experiments.
We used AT-1002, a peptide very similar to AT-1001 but an
agonist of the zonulin receptor, and found that at a high
concentration it could only increase small intestinal permeability.
Moreover, when both the agonist and antagonist were given
together the change in small intestinal permeability was
prevented, suggesting that they act through the same pathway.
These data suggest that the zonulin receptor is not present in the
colon of mice (as described in the rabbit) but we cannot exclude
thepossibilitythatthepeptidesweresimplydegradedduringtheir
Figure 6 Colonic secretion of interferon c (IFNc), tumour necrosis
factor a (TNFa) and myeloperoxidase (MPO) content at 17 weeks. (A
and B) The interleukin 10 gene-deficient (IL10
2/2) mice had a significant
increase in colonic secretion of these cytokines (p,0.05). This increase
was prevented by treatment with the zonulin peptide inhibitor AT-1001
(n=4–6). (C) The IL10
2/2 mice and the mice treated with the low dose
had a significant increase in MPO content (p,0.05). High-dose
treatment of AT-1001 prevented this increase (n=4–6).
Inflammatory bowel disease
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explanation is correct, these data suggest that the attenuation of
colitis observed in this study following treatment with AT-1001
was due to its effect in the small intestine.
It is important to recognise that in our experiment even
though colitis was ameliorated it was not abolished. Even in the
treated animals there was still histological evidence of mild
inflammation as well as MPO accumulation. There are several
potential explanations for this. First, animals received treatment
only from the age of 4 weeks and small intestinal permeability
was not reduced to ‘‘normal’’ until 8 weeks of age. Since the
animals are weaned from their mothers at 3–4 weeks of age it is
difficult to initiate this therapy any earlier. However, we know
that the permeability defect is present by 2 weeks of age and
this means that we did not completely remove this potential
inflammatory stimulus. Second, it is entirely possible that the
colonic disease in this animal model is not only generated by
events that occur proximally in the small intestine, but also by
direct interaction of the colonic bacterial flora with the IL10
deficient immune system. Thus, reducing antigen presentation
in the small intestine may not completely abrogate disease as
bacterial components could still induce secretion of proinflam-
matory cytokines in the colon and perpetuate inflammation.
82 9
In conclusion, we believe that these experimental data support
the hypothesis that, in a genetically predisposed host, increased
small intestinal permeability can contribute to the induction of
inflammatory disease. In the BB rat the disease is expressed in the
pancreaticisletcells,
20andreducingtheabnormalpermeabilitythat
precedes this disease with AT-1001 can ameliorate the resulting
diabetes.
21 The current study has extended these observations by
demonstratingthatintheIL10
2/
2mouseabnormalsmallintestinal
permeability not only precedes the development of colitis but it is
also aetiologically important. Reducing small intestinal perme-
ability with AT-1001 significantly attenuates colitis.
Figure 7 (A) Histological scoring. The interleukin 10 gene-deficient (IL10
2/2) mice and the animals treated with a low dose of the zonulin peptide
inhibitor AT-1001 had significantly increased histological scores as compared to the wild-type mice (*p,0.05). However, the group treated with a high
dose of AT-1001 had a histological score significantly lower than the untreated IL10
2/2 animals (**p,0.05), but this was still elevated significantly
from the wild-type (WT) controls (n=4–6). (B) Representative histology. All panels show colonic histology at 17 weeks of age. The upper panels (a, c,
e, g) were taken at620 magnification, while the lower panels (b, d, f, h) are the same regions at640. Panels a/b represent tissue from the wild-type
animals while panels c/d are from the IL10
2/
2 mice. A clear inflammatory infiltrate is observed in the lamina propria of these animals. Panels e/f are
from the low-dose group while g/h are from the high-dose treated animals. It can be appreciated that there is a significant reduction in the inflammatory
component of the lesion observed in these animals.
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